Abstracts tagged "autoimmune diseases"

Abstract Number: 0955 • ACR Convergence 2020
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
Rohit Aggarwal¹, Christina Charles-Schoeman², Joachim Schessl³, Zsuzsanna Bata-Csorgo⁴, Mazen Dimachkie⁵, Zoltan Griger⁶, Sergey Moiseev⁷, Chester Oddis⁸, Elena Schiopu⁹, Jiří Vencovský¹⁰, Beckmann Irene¹¹, Clodi Elisabeth¹¹, Todd Levine¹² and and the ProDERM Investigators¹³, ¹University of Pittsburgh, Pittsburgh, PA, ²University of California, Los Angeles, Los Angeles, CA, ³Städtisches Klinikum Karlsruhe, Karlsruhe, Germany, ⁴University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶University of Debrecen, Debrecen, Hungary, ⁷First Moscow State Medical University, Moscow, Russia, ⁸Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Michigan Medicine, Ann Arbor, MI, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria, ¹²Phoenix Neurological Associates, LTD, Phoenix, AZ, ¹³Different Institutions in several countries, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Intravenous immunoglobulin (IVIg) has long been…
Abstract Number: 1065 • ACR Convergence 2020
Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis
Adarsh Ravishankar¹, Daisy Yan², Christina Bax³, Josef Symon Concha², Bridget Shields⁴, Lisa Pappas-Taffer⁴, Rui Feng⁵, Joyce Okawa⁴ and Victoria Werth², ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia
Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…
Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Smriti Prasad¹, Samantha Black², Shivani Sharma³ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²The University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern, Dallas, TX
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
Abstract Number: 1560 • ACR Convergence 2020
Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry
Laila Abbas¹, Jennifer Day² and Heidi Jacobe³, ¹UT Southwestern Medical Center, Dallas, TX, ²University of Colorado, Denver, CO, ³University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Morphea is an autoimmune disorder causing sclerosis and inflammation of the skin and subcutaneous tissue. Facial morphea can cause substantial disfigurement and negative impact on quality of life. Existing clinical measures such…
Abstract Number: 1820 • ACR Convergence 2020
Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity
Margaret Markiewicz¹, Dayvia Russell² and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, Charleston, SC, ².Research Services, Ralph H. Johnson VA Medical Center, Charleston, SC,, Charleston
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease characterized by heterogeneous, multiorgan involvement with female predominance. Lupus nephritis is one of the…
Abstract Number: PP07 • ACR Convergence 2020
Improving Communication with My Physician Drastically Improved My Health
Whitney Carter¹, ¹Lupus and Allied Diseases Association, Inc., Pleasanton, CA
Background/Purpose: In 2011, at the age of 14, I was sent to the emergency room with a platelet count of 19. The hematologist diagnosed me…
Abstract Number: 0086 • ACR Convergence 2020
Geographic Distribution of Eosinophilic Fasciitis Cases in Massachusetts and Associated Environmental Triggers
Bina Kassamali¹, Anastasiya Muntyanu², Ruth Ann Vleugels³ and Avery LaChance³, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²McGill University, Montreal, QC, Canada, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Eosinophilic fasciitis (EF) is a rare fibrosing disorder of the fascia characterized by induration progressing proximally along the upper and lower extremities. Given the…
Abstract Number: 0451 • ACR Convergence 2020
Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
Sophia Verspohl¹, Tobias Holderried¹, Charlotte Behning², Peter Brossart¹ and Valentin Schaefer³, ¹Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
Abstract Number: 0627 • ACR Convergence 2020
Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series
Timothy Buckey¹, Mali Jurkowski¹, Kevin Lu², Roberto Caricchio² and Aruni Jayatilleke², ¹Temple University, Philadelphia, PA, ²Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: People with rheumatic diseases may be at high risk for poor outcomes related to COVID-19; on the other hand, immunomodulatory medications are used as…
Abstract Number: 0975 • ACR Convergence 2020
Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage
Xinghao Wang¹, Luz Blanco², Carmelo Carmona-Rivera³, Shuichiro Nakabo³, Hege Pedersen⁴, Zu-Xi Yu⁵ and Mariana Kaplan³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Canton, MI, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ⁵National Heart, Lung, and Blood Institute Pathology Core, Bethesda
Background/Purpose: Gasdermin D (GSDMD) is the key executioner of the inflammatory cell death mechanism pyroptosis. Recent reports have also implicated GSDMD in other mechanisms of…
Abstract Number: 1076 • ACR Convergence 2020
Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
Lois Bolko¹, Kevin Didier², Jean-Hugues Salmon¹, Makoto Miyara³, Segolene Toquet², Amelie Servettaz², Yves Allenbach³, Olivier Benveniste⁴ and Baptiste Hervier⁵, ¹Maison Blanche Hospital, Reims, Champagne-Ardenne, France, ²Robert Debre Hospital, Reims, Champagne-Ardenne, France, ³Sorbonne Université, Paris, Ile-de-France, France, ⁴Sorbonne Université, paris, France, ⁵Saint-Louis Hospital, Paris, Ile-de-France, France
Background/Purpose: Anti-Synthetase Syndrome (ASyS) is a rare systemic autoimmune disease defined by a combination of pulmonary, muscle, joint, and skin manifestations and the presence of…
Abstract Number: 1398 • ACR Convergence 2020
The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort
Sabrina Elliott¹, Duncan Moore² and Virginia Steen², ¹MedStar Georgetown Hospital, Alexandria, VA, ²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Systemic Sclerosis (SSc) patients with an isolated nucleolar patterned ANA (NUC ANA) make up about 15% of the SSc population, although the specific nucleolar…
Abstract Number: 1566 • ACR Convergence 2020
Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution
Christina Boutsicaris¹, Angelo Ciliberti², Elizabeth Lockerman¹, Faizah Siddique³ and Rochella Ostrowski¹, ¹Loyola University Medical Center, Maywood, IL, ²Loyola University Medical Center, Oak Park, IL, ³Loyola University Medical Center, Lombard, IL
Background/Purpose: Immune checkpoint inhibitors (ICI) have improved outcomes for many types of cancer, but the therapy is known to cause immune-related adverse events (IRAE). ICI…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: PP10 • ACR Convergence 2020
Patients with Relapsing Polychondritis (“RP”) and an Advocate Manufactured Custom Cloth Masks to Combat COVID-19: This Mask Project Provided a Sense of Purpose, Created Unity, Increased Awareness of RP, Facilitated Research, and Generated Hope
Isabel Bautista¹ and Michael Linn², ¹Relapsing Polychondritis Foundation, Wilmington, CA, ²Relapsing Polychondritis Foundation, New York, NY

Background/Purpose: In 2013, I was diagnosed with Relapsing Polychondritis ("RP"), a systemic inflammatory disease of unknown etiology that can be fatal. The disease affects multiple…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].